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Background: In clinical practice, concomitant treatment of orlistat with phentermine is 
commonly used off-label. However, clinical trials have not been performed to evaluate 
whether their combination improves metabolic parameters and cardiovascular risk factors 
other than weight loss. Therefore, we aimed to compare the efficacy of concomitant admin-
istration of orlistat and phentermine versus phentermine alone on the endothelial cell func-
tion in overweight and obese adults with back pain.
Methods: We conducted a 12-week, double-blinded, placebo-controlled clinical trial invol-
ving 114 patients with a body mass index of ≥30 (obese) or ≥27 (overweight) with weight- 
related comorbidities. We randomly assigned patients in a 1:1 ratio to receive orlistat 
(120mg) three times daily and phentermine (37.5mg) once daily, or a placebo three times 
daily and phentermine (37.5mg) once daily. Primary endpoint was changes in endothelium- 
dependent vasodilatation measured using ultrasound assessment of flow-mediated dilatation 
(FMD). Differences within groups after intervention were compared using the paired t-test or 
Wilcoxon signed-rank test. Differences in changes between the groups were calculated using 
an analysis of covariance after adjusting for each baseline value.
Results: Mean weight loss during the 12-week study period was 6.1kg in the orlistat/phentermine 
group and in the placebo/phentermine group. Adjusted mean changes in total and non-high-density 
lipoprotein cholesterol were significantly greater in the orlistat/phentermine group than in the 
placebo/phentermine group. Adjusted mean changes in endothelium-dependent FMD were sig-
nificantly greater in the orlistat/phentermine group than in the placebo/phentermine group (4.97 
±0.98% vs 2.05±0.99%, respectively; p=0.038). Changes in endothelium-independent nitrogly-
cerin-mediated dilatation were not significantly different between the groups.
Conclusion: Orlistat/phentermine significantly improved the vascular endothelial cell function 
compared with phentermine alone. Orlistat might have beneficial effects on the decrease of the risk 
of cardiovascular disease, especially in overweight and obese patients with comorbidities.
Trial Registration: ClinicalTrails.gov number, NCT03675191.
Keywords: obesity, orlistat, phentermine, endothelial cell function
Introduction
The prevalence of obesity is gradually increasing globally;1 in Korea, its prevalence 
has increased from 29.7% in 2009 to 32.4% in 2015.2 The incidence of cardiovas-
cular diseases (CVDs) has also increased with the prevalence of obesity.
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The endothelium, which is composed of a monolayer 
of endothelial cells, maintains vascular homeostasis by 
producing and releasing vasoactive molecules.3 Because 
the endothelium regulates the micro- and macrocirculation 
of blood flow, endothelial dysfunction is considered to be 
an early indicator of CVD.4 Obesity and its related comor-
bidities, such as hypertension and hypercholesterolemia, 
are risk factors for endothelial cell dysfunction,5 whereas 
weight loss and improvement of metabolic parameters 
through lifestyle modifications improve endothelial cell 
function.6 Several studies also showed that pharmacologi-
cal treatments such as statin and saxagliptin have 
a beneficial effect on endothelial function.7,8
Phentermine hydrochloride (HCl), a sympathomimetic 
amine, is the most commonly prescribed anti-obesity drug in 
the United States and other countries.9 The short-term efficacy 
of phentermine has been demonstrated in terms of weight loss 
and improved metabolic parameters.10 However, concerns of 
increased heart rate (HR) and blood pressure (BP) related to its 
sympathomimetic effects remain.11 Orlistat, a gastric and pan-
creatic lipase inhibitor without effects on the central nervous 
system has been approved for several years for long-term 
weight management.12 Combined with lifestyle modification, 
orlistat treatment is associated with small, but meaningful 
weight loss, and reductions in BP and total cholesterol (TC) 
and low-density lipoprotein cholesterol (LDL-C).13 In addi-
tion, several studies have reported the anti-inflammatory, anti-
oxidant, and antitumor effects of orlistat.14,15
Owing to their differing pharmacology, the concomi-
tant treatment of orlistat with phentermine is commonly 
used off-label in clinical practice.16 However, no clinical 
trials have been conducted to assess whether the combina-
tion therapy of these two drugs improves metabolic para-
meters and cardiovascular risk factors other than weight 
loss. We investigated that adding orlistat to phentermine 
has a positive effect on endothelial cell function compared 
with phentermine alone in obese and overweight adults 
with weight-related comorbidities.
Methods
Study Design and Patients
This study was a randomized, double-blinded, placebo- 
controlled 12-week clinical trial. The protocol was 
approved by the institutional review board of Yongin 
Severance Hospital (IRB No. 9–2018-0004) and registered 
with ClinicalTrails.gov (number: NCT03675191). This 
study was performed in compliance with the Declaration 
of Helsinki. Written consent was obtained from all patients 
prior to participation.
Patients were recruited from October 2018 to 
May 2019 at Yongin Severance Hospital (Yongin, South 
Korea). Eligible patients aged 20–70 years were obese 
(body mass index [BMI]≥30 kg/m2) or overweight 
(BMI≥27 kg/m2) with at least one weight-related compli-
cation (eg, diabetes, prediabetes, hypertension, dyslipide-
mia, or metabolic syndrome). Exclusion criteria included 
the following contraindications for the use of phentermine 
or orlistat (Supplementary information).
Randomization and Masking
Participants were randomly assigned in a 1:1 ratio to 
receive a placebo three times a day plus phentermine 
HCl (37.5 mg) once daily, or orlistat (120 mg) three 
times a day plus phentermine HCl (37.5 mg) once daily. 
Subjects were instructed that if they a skipped meal, they 
should also skip the corresponding orlistat dose. 
Randomization was performed using a centralized compu-
ter-generated system. Investigators and patients were 
masked to treatment assignment throughout the study.
Procedures and Endpoints
Study visits were scheduled at screening; baseline; and at 
4, 8, and 12 weeks. Body weight, waist circumference 
(WC), systolic and diastolic BP were measured at each 
visit. Laboratory tests, HR variability, body composition 
measurement, and flow-mediated dilatation (FMD) were 
measured at baseline and 12 weeks. Health-related (physi-
cal activity, smoking, alcohol consumption) and food 
intake (using a 24-h recall method) questionnaires were 
administered at baseline and 12 weeks. Participants were 
categorized into never smoker, ex-smoker, and current 
smoker groups. An alcohol drinker was defined as 
a person who drinks alcohol more than once a month. 
Physical activity was defined as undertaking light to mod-
erate exercise more than two times per week. We used 
a binary variable with the presence or absence of a history 
of hypertension, dyslipidemia, or diabetes, according to 
a self-reported questionnaire.
Weight and body composition (skeletal muscle mass, 
fat mass, and percent body fat) were assessed by conduct-
ing bioelectrical impedance analysis using the Inbody720 
body composition analyzer (Biospace, Seoul, South 
Korea). WC was measured using a measuring tape on the 
horizontal plane midway between the lowest rib and iliac 
crest.
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Blood samples were obtained after more than 8 
h fasting. At each visit, all participants were consulted 
about their diet and exercise by a doctor and advised to 
follow a hypocaloric diet (consuming 500 kcal below 
individual estimated energy requirements per day) and 
light- (~3 metabolic equivalent) to moderate-intensity 
exercise (3–6 metabolic equivalent) more than three 
times per week.
The primary efficacy endpoint was changed in FMD 
based on ultrasound assessment. Secondary endpoints 
were changed in weight, WC, BMI, fat mass, fat, percen-
tage, serum lipid levels, C-reactive protein (CRP), and 
glycemic variables (fasting glucose, fasting insulin, 
HOMA-IR).
Safety and Compliance
Safety assessment consisted of the assessment of adverse 
events and use of concomitant medications, measurement of 
vital signs (BP, HR), laboratory tests (aspartate aminotransfer-
ase [AST], alanine aminotransferase [ALT], serum creatinine 
[Cr]), and echocardiography. Adverse events and the use of 
concomitant medications were assessed and vital signs were 
measured at each visit. A trained and certified sonographer 
conducted all echocardiography examinations using the SSH- 
880CV ultrasound system (Artida, Tokyo, Japan) at screening 
and 12 weeks. A cardiologist supervised and interpreted the 
results. Drug compliance was measured by counting the 
remaining pills at each visit. The compliance rate was set at 
>70%. For orlistat, the compliance rate was determined after 
taking into consideration the number of meals skipped.
Assessment of the Vascular Endothelial 
Cell Function
Endothelium-dependent FMD was assessed according to 
the guidelines for the ultrasound assessment of endothe-
lial-dependent flow-mediated vasodilatation of the brachial 
artery introduced by the International Brachial Artery 
Reactivity Task Force.17 FMD was conducted after 8–12 
h of fasting in a quiet, temperature-controlled room. 
Patients were not permitted to take antihypertensive med-
ication (calcium channel blocker, nitrate, beta-blocker, 
angiotensin-converting-enzyme inhibitor, angiotensin II 
receptor blockers) within 48 h and aspirin and nonsteroidal 
anti-inflammatory drugs within 10 days before FMD. 
Patients were not permitted to consume caffeine or 
smoke within 8 h before FMD. A sphygmomanometer 
cuff was placed above the antecubital fossa on the forearm 
and inflated to at least 50 mmHg above patients’ SBP. 
Images of the brachial artery were recorded before infla-
tion and at 30 s, 45 s, 60 s, 75 s, and 90 s after deflation of 
the cuff. After a 10-min rest, 0.6 mg of sublingual nitro-
glycerin was administered, and endothelium-independent 
dilatation was assessed. Images were obtained before 
nitroglycerin administration and at 3 and 4 min after 
nitroglycerin administration. Endothelium-dependent 
(FMD) and endothelium-independent (nitroglycerin- 
mediated dilatation, NMD) vasodilatation were calculated 
as follows: FMD (%) or NMD (%) = ([maximal diameter 
− baseline diameter]/baseline diameter) � 100. The same 
blinded investigator performed all FMD assessments. The 
intraclass correlation coefficient was 0.979 (0.970–0.985).
Statistical Analysis
We conducted the Kolmogorov–Smirnov test of normality 
to examine the normal distribution of values before analy-
sis. Data are presented as mean±standard deviations or 
median (interquartile ranges). For efficacy analyses, we 
used data from the full analysis set, which included all 
patients who underwent randomization and had at least 
one assessment. Missing values were imputed using the 
last-observation-carried-forward method. Differences in 
baseline characteristics between the placebo/phentermine 
and orlistat/phentermine groups were compared using the 
independent t-test or Mann–Whitney U-test. Differences 
after intervention within groups were compared using the 
paired t-test or Wilcoxon signed-rank test. Differences in 
changes between the groups were calculated using an 
analysis of covariance after adjusting for each baseline 
value. Significance tests were two-sided, with an alpha 
value of 0.05. All statistical analyses were performed 
using SPSS software version 25.0 (IBM Corp., Armonk, 
NY, USA).
For the calculation of sample size, no randomized con-
trolled trial has been performed to investigate the effect of 
orlistat on the endothelial cell function using FMD. Because 
LDL-C was reported to be significantly correlated with FMD 
in previous studies,18,19 we calculated the effect size based on 
absolute LDL-C changes between the orlistat (−0.53±0.65) 
and placebo/phentermine (−0.09±0.8; effect size=0.6) 
groups.20 We assumed that the effect size would be similar 
to the effect size of FMD. A Cohen’s effect size of 0.6 
indicates a medium to large effect size. Sample size was 
calculated using an independent two-sample t-test with 80% 
power, a two-sided significance level of 5%, and a dropout rate 
of 20%.
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Results
Subject disposition is shown in Figure 1. A total of 113 
subjects were randomized to receive placebo/phentermine (N 
= 56) or orlistat/phentermine (N = 57). Of these, 96 subjects 
(46 assigned to placebo/phentermine, and 50 assigned to orli-
stat/phentermine) completed the full 12-week trial.
Baseline characteristics were also similar between the 
orlistat/phentermine (n=57) and placebo/phentermine 
(n=55) groups in terms of age, sex, and BMI, and meta-
bolic parameters and FMD values were well-balanced 
between the groups (Table 1).
Table 2 shows the characteristics and changes in the 
two groups before and after intervention after adjusting 
for each baseline value. Both treatments led to clinically 
significant weight loss (−6.1kg vs −6.0 kg; p=0.94). Body 
composition measures (fat mass, percent fat, and fat-free 
mass) and WC decreased in both groups. SBP and DBP 
decreased and HR increased slightly in both treatment 
groups. Fasting insulin levels and HOMA-IR were sig-
nificantly decreased in both groups. However, fasting 
glucose levels were not altered in both groups. Adjusted 
mean changes in anthropometric measurements (weight, 
WC, fat mass, percent body fat), BP, CRP, glucose, insu-
lin, HOMA-IR, and caloric intake were not different 
between the two groups after adjusting for each baseline 
value.
Table 3 shows the adjusted mean changes in the concen-
trates of lipids and FMD. Changes in TC and non-HDL-C were 
significantly greater in the orlistat/phentermine group than in 
the placebo/phentermine group (−0.62±0.07 mmol/l vs −0.32 
±0.07 mmol/l, respectively, p=0.01; −0.53±0.07 mmol/l vs 
−0.30±0.07 mmol/l, respectively, p=0.02). Although no statis-
tical significance was found, adjusted mean LDL was further 
decreased in the orlistat/phentermine group than in the pla-
cebo/phentermine group (−0.36±0.05 mmol/l vs −0.21±0.06 
mmol/l, p=0.05). Adjusted mean changes in TG were not 
significantly different between the groups. Adjusted mean 
changes in endothelium-dependent FMD were significantly 
greater in the orlistat/phentermine group than in the placebo/ 
phentermine group (4.97±0.98% vs 2.05±0.99%, respectively; 
p=0.04), whereas changes in endothelium-independent NMD 
were not significantly different between the groups.
Changes in lipids, FMD, and NMD were similar in the 
per protocol set (n=96) (Supplementary Table 1).
Figure 1 Flow chart of study cohort enrollment, allocation, follow-up, and completion.
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Table 1 Baseline Characteristics of Study Participants
N Placebo/Phentermine Orlistat/Phentermine p-value
55 57
Women, No (%) 43 (78.6) 44 (77.2) 0.86
Age, years 46.0 ± 11.3 45.5 ± 12.5 0.84
Physical measurement
Height, cm 163.0 ± 9.0 164.0 ± 9.6 0.56
Weight†, kg 78.3 (72.2, 90.5) 80.3 (72.6, 96.3) 0.56
Body mass index, kg/m2† 29.8 (27.6, 33.6) 30.8 (28.1, 33.5) 0.42
Waist circumference, cm 102.8 ± 9.5 104.1 ± 9.5 0.47
Fat free mass, kg† 47.3 (42.7, 53.9) 47.7 (42.1, 59.5) 0.69
Fat mass, kg† 30.5 (28.5, 37.1) 32.4 (28.0, 39.5) 0.52
Percent body fat, % 39.9 ± 5.7 40.0 ± 6.9 0.99
Waist hip ratio† 0.95 (0.93, 0.97) 0.95 (0.93, 0.98) 0.73
SBP (mmHg) 128.6 ± 14.2 127.8 ± 15.5 0.79
DBP (mmHg) 86.3 ± 12.5 85.6 ± 11.7 0.78
Heart rate (bpm) 72.8 ± 8.8 71.8 ± 9.5 0.55
Comorbid condition, n (%)
HTN 33 (58.9) 30 (52.6) 0.50
Diabetes 6 (10.7) 12 (21.1) 0.13
Hypercholesterolemia 22 (39.3) 16 (28.1) 0.21
Medication history
HTN medication 13 (23.2) 11 (19.3) 0.61
Diabetes medication 4 (7.1) 6 (10.5) 0.53
Dyslipidemia medication 13 (23.2) 9 (15.8) 0.32
Health-related behavior
Smoking, n (%) 0.72
Non-smoker 30 (66.7) 35 (70.0)
Ex-smoker 8 (17.8) 6 (12.0)
Current smoker 7 (15.6) 9 (18.0)
Alcohol consumption, n (%) 21 (47.7) 26 (54.2) 0.54
Total calorie intake (kcal) 1522 (1160, 1739) 1458.7 (1238, 1294) 0.69
Laboratory test
WBC (cells/㎕) 6662 ± 173 6577 ± 173 0.79
(Continued)
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Adverse Events
Percentages of patients with adverse events in the full analysis 
set were similar between the placebo/phentermine (n=18 
[32.1%]) and orlistat/phentermine (n=23 [40.4%]) groups 
(Supplementary Table 2). Safety was measured using BP, 
HR, and echocardiography. Echocardiography showed no 
valvular heart diseases, pulmonary artery hypertension, or 
other significant findings (Supplementary Table 3).
Discussion
In this randomized, double-blinded, placebo-controlled 
study, we found that endothelial-dependent FMD signifi-
cantly improved in the orlistat/phentermine group com-
pared with the placebo/phentermine group in obese and 
overweight patients with comorbidities.
In this study, mean weight loss was decreased by approxi-
mately 6kg in both groups, which indicates that the concomi-
tant treatment of orlistat with phentermine does not provide 
additive weight loss effects. Our findings are similar to those of 
previous studies that reported weight loss in orlistat plus sibu-
tramine vs sibutramine alone.21,22 Moreover, WC, BP, CRP, 
and insulin levels were significantly improved in both groups, 
and adjusted mean changes were similar between the groups. 
We believe that these metabolic parameters were mainly 
affected by weight loss. Further, HDL-C significantly 
decreased in the orlistat/phentermine group. Although the 
exact reason for this decrease in HDL in the orlistat/phenter-
mine group is unclear, HDL-C simultaneously decreases with 
decreasing serum cholesterol because orlistat inhibits intestinal 
fat digestion and dietary fat absorption by approximately 
30%.23
In contrast to previous studies that focused on weight 
loss as a primary endpoint, we investigated the effect of 
concomitant therapy with orlistat and phentermine on the 
endothelial cell function. The orlistat plus phentermine 
group, along with mild exercise and calorie reduction, 
showed greater improvement in FMD in overweight and 
obese adults than the phentermine alone group.
Table 1 (Continued). 
N Placebo/Phentermine Orlistat/Phentermine p-value
55 57
CRP (mg/L) 1.25 (0.73, 2.08) 1.50 (0.60, 2.70) 0.92
AST (IU/L) 24.0 (19.3, 30.8) 25.0 (19.0, 33.5) 0.57
ALT (IU/L) 25.0 (17.3, 31.8) 25.0 (15.5, 44.0) 0.47
Serum creatinine (mg/dl) 0.75 (0.68, 0.86) 0.73 (0.68, 0.87) 0.72
Glucose (mmol/l) 5.61 (5.38, 6.11) 5.72 (5.33, 6.43) 0.27
Insulin (mU/L) 8.65 (6.88, 12.98) 8.20 (5.60, 12.85) 0.40
HOMA-IR 2.27 (1.77, 3.49) 2.05 (1.39, 3.66) 0.71
Triglyceride (mmol/l) 1.47 (1.04, 1.78) 1.36 (0.98, 1.68) 0.62
Total cholesterol (mmol/l) 5.33 ± 1.04 5.02 ± 0.92 0.10
LDL cholesterol (mmol/l) 3.40 ± 0.80 3.10 ± 0.62 0.02
Non-HDL cholesterol (mmol/l) 4.00 ± 1.03 3.66 ± 0.88 0.07
HDL cholesterol (mmol/l) 1.34 ± 0.23 1.36 ± 0.33 0.08
Flow-mediated dilatation
FMD (%) 11.2 ± 5.4 10.6 ± 6.1 0.56
NMD (%) 10.4 ± 7.3 9.6 ± 6.2 0.62
Notes: Data are presented as mean±standard deviations, median (interquartile ranges), or number (percentage); p-values calculated using independent two-sample t-test or 
Mann–Whitney U-test; †Continuous values calculated using Mann–Whitney U-test, and categorical values calculated using chi-square test. 
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN, hypertension; WBC, white blood cell; CRP, C-reactive protein; AST, aspartate 
aminotransferase; ALT, alanine aminotransferase; HOMR-IR, homeostasis model assessment of insulin resistance; LDL-C, low-density lipoprotein cholesterol; HDL-C, high- 
density lipoprotein cholesterol; FMD, flow-mediated dilatation; NMD, nitroglycerin-mediated dilatation.
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Previous studies have shown the positive role of orlistat in 
endothelial cell function. Sekuri et al24 and Liu et al25 showed 
that orlistat treatment improves FMD in young obese women 
(aged 18–34 years) and obese adults with hypertension. 
Bergholm et al’s randomized controlled trial6 showed that 
orlistat treatment improves endothelium-dependent vasodila-
tation using a blood flow response to acetylcholine in obese 
women with gestational diabetes, despite similar weight loss 
reported in the orlistat and placebo groups. We also hypothe-
sized that adding orlistat could improve endothelium- 
dependent vasodilatation regardless of weight loss. In this 
study, endothelium-dependent FMD was significantly 
improved in the orlistat/phentermine group only. NMD was 
not significantly affected in either group, indicating that orlistat 
has a positive role in the endothelium.
In the early stages when blood vessel is under shear stress, 
a calcium-activated potassium channel in the endothelium is 
opened, which activates endothelial nitric oxide synthase 
(eNOS) and leads to increased NO production to protect vessel 
damage.17 However, prolonged endothelial shear stress 
reduces the bioavailability of NO by decreasing eNOS 
mRNA and protein expression and promoting oxidative stress 
and proinflammatory cytokines.26,27 Inflammation has been 
known to decrease the endothelial cell function and a key factor 
in pathophysiology in obesity and CVD.28 While the exact 
mechanism involved in our results is unclear, the anti- 
inflammatory and anti-cancer effects of orlistat could be pos-
sible explanations. Samuelsson et al29 reported that orlistat 
treatment for 1 year significantly reduced tumor necrosis factor 
alpha levels, a potent inflammatory mediator, compared with 
placebo treatment. In our study, CRP tended to be reduced 
more in the orlistat/phentermine group than in the placebo/ 
phentermine group. However, no significant differences were 
found in CRP reduction in both groups, which might be due to 
the short duration of orlistat treatment. A long-term study is 
warranted to clarify the change in CRP and anti-inflammatory 
effects of orlistat.
Another explanation of the effects of orlistat on the 
endothelial cell function is that orlistat is a novel fatty acid 
synthase inhibitor.14,15 A previous study revealed that ele-
vated free fatty acids (FFAs) are related to impaired 
endothelial cell function.30 FFA not only reduces NO 
production in endothelial cells by downregulating the 
AMPK/PI3K/Akt/eNOS signaling31 but also disrupts cal-
cium signaling-mediated NO production.32 FFA, per se, is 
a source of reactive oxygen species, which leads to oxida-
tive stress that impairs the endothelium.33 Therefore, orli-
stat treatment could lead to an improvement in endothelial 
functions and vasodilatation.
Finally, despite identical weight loss between the groups, 
we found that the orlistat/phentermine group had a greater 
reduction of TC and non-HDL and a mild, but greater, reduc-
tion of LDL cholesterol than the placebo/phentermine group. 
Feron et al34 showed that hypercholesterolemia decreases NO 
production in the endothelium by upregulating caveolin pro-
tein and inhibiting eNOS activity. Therefore, in hypercholes-
terolemia, reduced bioavailability of NO leads to impairment 
of endothelium-dependent vasodilation. Thus, reduction of 
serum cholesterol might have led to the improvement in the 
endothelial cell function observed in this study.
Table 3 Changes in Lipids and Endothelial Cell Function in the Placebo/Phentermine and Orlistat/Phentermine Groups at Baseline and 
12 Weeks
Placebo/Phentermine (N=55) Orlistat/Phentermine (N=57)
Baseline 12 Weeks Changes Baseline 12 Weeks Changes p-value†
Triglyceride 1.47(1.04,1.78)* 1.13(0.93, 1.47)* −0.35±0.08 1.36(0.98,1.68) 1.18(0.82, 1.59)* −0.42±0.08 0.55
Total cholesterol 5.33 ±1.04 4.96 ±1.00* −0.32±0.07 5.02 ±0.92 4.45 ±0.75* −0.62±0.07 0.01
LDL cholesterol 3.40 ±0.80 3.15 ±0.76* −0.21±0.06 3.10 ±0.62 2.78 ±0.55* −0.36±0.05 0.05
Non-HDL cholesterol 3.99 ±1.04 3.64 ±0.96* −0.30±0.07 3.66 ±0.88 3.18 ±0.69* −0.53±0.07 0.02
HDL cholesterol 1.33 ± 0.24 1.32 ± 0.23 −0.03±0.02 1.36 ±0.33 1.27 ±0.26* −0.09±0.02 0.01
FMD (%) 11.2±.5.4 13.0±6.6 2.05±0.99 10.6±6.1 15.8±8.2* 4.97±0.98 0.04
NMD (%) 12.7±6.3 14.3±6.0 1.09±0.86 11.0±5.5 13.0±6.3 2.49±0.83 0.70
Notes: Data are presented as mean ± standard deviations or median (interquartile ranges). The values of changes are presented as mean ± standard errors. *p-value<0.05; 
†p-value; differences in changes between the two groups calculated using an analysis of covariance after adjusting for each baseline value. 
Abbreviations: LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; FMD, flow-mediated dilatation; NMD, nitroglycerin-mediated 
dilatation.
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This study has some limitations. This study has some 
limitations. First, although FMD is known as a standard 
tool for the noninvasive assessment of conduit artery 
endothelial function, it requires highly trained technicians 
and could be affected by temperature and environmental 
factors. Therefore, a skilled investigator conducted FMD 
in a quiet and dark room in this study. Second, the treat-
ment duration (12 weeks) was relatively short. Third, this 
study included Korean subjects only; therefore, our results 
may not be generalizable to different ethnicities. Fourth, 
there was no treatment group that received placebo only.
Conclusions
This study demonstrated that orlistat improves endothelial- 
dependent FMD in obese adults independent of weight loss. 
Adding orlistat to phentermine could be helpful for reducing 
cardiovascular risk by improving the endothelial cell func-
tion, particularly in overweight patients with comorbidities 
or obese patients. More data about the concomitant treat-
ment of orlistat with phentermine are needed.
Abbreviations
BMI, body mass index; BP, blood pressure; CRP, C-reactive 
protein; CVD, cardiovascular disease; DBP, diastolic blood 
pressure; eNOS, endothelial nitric oxide synthase; FFA, free 
fatty acid; FMD, flow-mediated dilatation; HDL-C, high- 
density lipoprotein cholesterol; HOMA-IR, homeostasis 
model assessment of insulin resistance; HR, heart rate; LDL- 
C, low-density lipoprotein cholesterol; NMD, nitroglycerin- 
mediated dilatation; SBP, systolic blood pressure; TC, total 
cholesterol; VAS, visual analog scale; WBC, white blood 
cell; WC, waist circumference.
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